Basic Information
| LncRNA/CircRNA Name | HOXA-AS2 |
| Synonyms | HOXA-AS2, HOXA3as |
| Region | GRCh38_7:27107777-27134302 |
| Ensemble | ENSG00000253552 |
| Refseq | NR_122069 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | gastric cancer |
| ICD-0-3 | C16 |
| Methods | Microarray, qPCR, Western blot, Luciferase reporter assay etc. |
| Sample | gastric cancer tissues, cell lines (BGC823, SGC7901, AGS) |
| Expression Pattern | up-regulated |
| Function Description | Here, we reported that HOXA cluster antisense RNA2 (HOXA-AS2), a 1048bp RNA, was upregulated in GC. Increased HOXA-AS2 expression in GC was associated with larger tumor size and higher clinical stage; patients with higher levels of HOXA-AS2 expression had a relatively poor prognosis. HOXA-AS2 could be an oncogene for GC partly through suppressing P21, PLK3, and DDIT3 expression; HOXA-AS2 may be served as a candidate prognostic biomarker and target for new therapies in human GC. |
| Pubmed ID | 26384350 |
| Year | 2015 |
| Title | Long noncoding RNA HOXA-AS2 promotes gastric cancer proliferation by epigenetically silencing P21/PLK3/DDIT3 expression. |
External Links
| Links for HOXA-AS2 | GenBank HGNC NONCODE |
| Links for gastric cancer | OMIM COSMIC |